Kymera Therapeutics (KYMR) Capital Expenditures (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Capital Expenditures data on file, last reported at $434000.0 in Q1 2026.

• On a quarterly basis, Capital Expenditures fell 7.07% year-over-year to $434000.0 in Q1 2026; TTM through Mar 2026 was $7.1 million, a 20.8% increase from a year earlier, with the FY2025 full-year figure at $7.2 million, down 44.2% from the prior year.
• Capital Expenditures for Q1 2026 stood at $434000.0, down from $5.8 million in the prior quarter.
• Over the last five years, Capital Expenditures for KYMR reached as high as $10.8 million in Q2 2023 and fell as low as -$14.8 million in Q3 2023.
• Historically, Capital Expenditures has averaged $1.2 million across 5 years, with a median of $695000.0 in 2025.
• On a YoY basis, Capital Expenditures climbed as much as 1365.03% in 2023 and fell as far as 1285.96% in 2023.
• Year by year, Capital Expenditures stood at -$1.5 million in 2022, then surged by 37.95% to -$909000.0 in 2023, then jumped by 202.97% to $936000.0 in 2024, then surged by 521.9% to $5.8 million in 2025, then plunged by 92.54% to $434000.0 in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $434000.0 in Q1 2026, $5.8 million in Q4 2025, and $181000.0 in Q3 2025.